Therese Heinonen, DVM, is the Associate Director of Medical and Scientific Affairs at the Montréal Heart Institute Co-ordinating Center. Dr Heinonen’s clinical research projects focus on cardioprotection, neuroprotection, atrial fibrillation, heart failure, atherosclerosis, cardiovascular imaging, and lipid modification. Her additional areas of interest include strategies to improve clinical trial design and methodology. She has authored over 40 publications and managed over 30 clinical trials, many of which have focused on cardiovascular biomarkers and imaging technologies. Dr Heinonen has worked as a consultant to government institutions, pharmaceutical companies, and diagnostic companies. In 2003, Dr Heinonen began organizing the annual Cardiovascular Biomarkers and Surrogate Endpoints Symposium, and in 2006 co-founded the International Partnership for Critical Markers of Disease, a non-profit organization aiming to accelerate the identification, validation, and appropriate application of biomarkers in cardiovascular and related diseases. Dr Heinonen received training in molecular biology at Merck Research Laboratories, and was a member of the Pfizer Global Research and Development Cardiovascular Senior Management team, where she made significant contributions to the clinical development of Lipitor. She is a graduate of Michigan State University College of Veterinary Medicine.